184954-75-4

Basic information

• Product Name: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE
• Synonyms: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE;1-N-Boc-cis-1,2-cyclohexyldiamine;1-N-Boc-1,2-cis-cyclohexyldiamine (Racemic);CarbaMic acid, (2-aMinocyclohexyl)-, 1,1-diMethylethyl ester, cis-;N-Boc-cis-1,2-cyclohexanediaMine;N-[(1R,2S)-2-aMinocyclohexyl]-, CarbaMic acid, 1,1-diMethylethyl ester;cis-N1-(tert-Butoxycarbonyl)-1,2-cyclohexanediaMine;Cis 1N-Boc-cyclohexane-1,2-diaMine
• CAS NO: 184954-75-4
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Mol File: 184954-75-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 46 °C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(184954-75-4)
• EPA Substance Registry System: 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE(184954-75-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/39
• Hazardous Substances Data: 184954-75-4(Hazardous Substances Data)

Usage

General Description

1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE is a chemical compound with the molecular formula C14H28N2O2. It is a diamine derivative that contains a BOC (tert-butoxycarbonyl) protecting group on the nitrogen atom. 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE is commonly used as a building block in organic synthesis, particularly in the synthesis of pharmaceuticals and agrochemicals. Its cyclohexyl backbone and amine groups make it a valuable reagent for the preparation of various heterocyclic compounds and complex organic molecules. Additionally, the BOC protecting group allows for controlled reactivity and selective functionalization, making 1-N-BOC-1,2-CIS-CYCLOHEXYLDIAMINE a versatile and important intermediate in chemical synthesis.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1436-59-5 cis-cyclohexane-1,2-diamine 

Relevant articles and documents

From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.

Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists

We describe the design, synthesis, and evaluation of novel disubstituted cyclohexanes as potent CCR2 antagonists. Exploratory SAR studies led to the cis-disubstituted derivative 22, which displayed excellent binding affinity for CCR2 (binding IC50/s

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.